Development of Products. Lilly will in its discretion determine which, if any, such Hit(s), or Derivative(s) of Hit(s), will be approved as an Approved PTAC Compound. Lilly will be responsible for all pre-clinical and clinical development, including all regulatory filings, of Hits and Approved PTAC Compounds arising out of this Agreement. Lilly shall have discretion and control over the conduct of, and all activities associated with, the development or abandonment of any Approved *** CONFIDENTIAL TREATMENT REQUESTED
Appears in 3 contracts
Sources: Collaborative Research and License Agreement (Aurora Biosciences Corp), Collaborative Research and License Agreement (Aurora Biosciences Corp), Collaborative Research and License Agreement (Aurora Biosciences Corp)